PTC Therapeutics Should Be Bought On Today's Sell-Off, Says Citi
September 29, 2017 at 09:43 AM EDT
Citi analyst Joel Beatty, while conceding the FDA is unlikely to approve Translarna after yesterday's 10-1 panel vote in favor of needing more data, recommends buying shares of PTC Therapeutics today on the sell-off.
